The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...
Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NCFB). The US regulator cleared DPP1 ...
TimesMachine is an exclusive benefit for home delivery and digital subscribers. Full text is unavailable for this digitized archive article. Subscribers may view the full text of this article in its ...
BACKGROUND An obstructive defect is usual in bronchiectasis, but the pathophysiological basis of airflow obstruction remains uncertain. High resolution computed tomographic (CT) scanning now allows ...
Correspondence to Professor Adam T Hill, Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, Scotland EH16 4SA, UK; adam.hill318{at}nhs.net The new British Thoracic Society ...
Long before the Roman Empire came along, the Ancient Greeks controlled much of southern Italy. From the 8th to the 5th centuries BC, intrepid Greek settlers transformed this region into a mosaic of ...
In North American history, an 800-year saga unfolds, echoing the clash for land and wealth. Indigenous nations battled each other and the encroaching Europeans, marking a defiant struggle for survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback